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Abstract
Background: Cancer/testis (CT) genes have expression normally restricted to the testis, but become activated during
oncogenesis, so they have excellent potential as cancer-specific biomarkers. Evidence is starting to emerge to indicate
that they also provide function(s) in the oncogenic programme. Human TEX19 is a recently identified CT gene, but a
functional role for TEX19 in cancer has not yet been defined.
Methods: siRNA was used to deplete TEX19 levels in various cancer cell lines. This was extended using shRNA to
deplete TEX19 in vivo. Western blotting, fluorescence activated cell sorting and immunofluorescence were used
to study the effect of TEX19 depletion in cancer cells and to localize TEX19 in normal testis and cancer cells/tissues.
RT-qPCR and RNA sequencing were employed to determine the changes to the transcriptome of cancer cells depleted
for TEX19 and Kaplan-Meier plots were generated to explore the relationship between TEX19 expression and prognosis
for a range of cancer types.
Results: Depletion of TEX19 levels in a range of cancer cell lines in vitro and in vivo restricts cellular proliferation/
self-renewal/reduces tumour volume, indicating TEX19 is required for cancer cell proliferative/self-renewal potential.
Analysis of cells depleted for TEX19 indicates they enter a quiescent-like state and have subtle defects in S-phase
progression. TEX19 is present in both the nucleus and cytoplasm in both cancerous cells and normal testis. In
cancer cells, localization switches in a context-dependent fashion. Transcriptome analysis of TEX19 depleted cells
reveals altered transcript levels of a number of cancer-/proliferation-associated genes, suggesting that TEX19
could control oncogenic proliferation via a transcript/transcription regulation pathway. Finally, overall survival
analysis of high verses low TEX19 expressing tumours indicates that TEX19 expression is linked to prognostic
outcomes in different tumour types.
Conclusions: TEX19 is required to drive cell proliferation in a range of cancer cell types, possibly mediated via an
oncogenic transcript regulation mechanism. TEX19 expression is linked to a poor prognosis for some cancers and
collectively these findings indicate that not only can TEX19 expression serve as a novel cancer biomarker, but may
also offer a cancer-specific therapeutic target with broad spectrum potential.
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Background
The ability of cancer cells to self-renew and undergo
phenotypic changes has led to the postulate that some
have similarities to germline cells and/or stem cells [1, 2],
leading to the suggestion that a key feature of oncogenesis
is a cellular soma-to-germline transition [1, 3–6]. This is
supported by the finding that tumours in Drosophila
melanogaster activate a large cohort of germline genes
during oncogenesis and that some of these are essential
for tumour progression [7–9]. Analysis of gene expression
in human tumours indicates that a similar pattern of
germline gene activation is also apparent, inferring a pos-
sible functional requirement [3].
One major group of germline genes is termed the cancer/
testis (CT) genes. These encode cancer/testis antigens
(CTAs), proteins that are normally only present in healthy
adult testis, but are also found in a wide range of cancers
[10–12]. Little is currently known about the function in the
testis for most of these proteins, but evidence is emerging
to indicate that CTAs function in oncogenic processes,
supporting the idea of a functional soma-to-germline
transition [12, 13]. Examples include regulation of cel-
lular mitotic fidelity [14–20] and invasiveness [21–25].
These findings offer attractive new avenues for cancer-
specific therapeutic targeting via inhibition of oncogenic
CTA functions [2, 11–13].
Recently, a pipeline for the identification of new CT
genes was developed [26, 27]. One of the genes identified
was Testis Expressed 19 (TEX19), a mammalian specific
gene with a poorly defined function [28, 29]; subsequently,
this expression profile was verified [30] and TEX19 pro-
tein was shown to be a CTA [31].
In rodents, the TEX19 orthologue has undergone du-
plication to generate a paralogue pair of genes, Tex19.1
and Tex19.2 [29]. Both murine genes are differentially
expressed, with Tex19.2 expression restricted to the
developing gonadal ridge and adult testis and Tex19.1
being expressed in the adult testis, the placenta and in
the early embryo, in a pattern matching the pluripotency
marker gene Oct4 [29], although expression control
mechanisms of the two genes is distinct [32]. Tex19.1 is
expressed in embryonic stem cells (ESCs) and whilst this
might infer a functional role in stemness [29], Tex19.1-/-
ESCs have no overt stemness/ proliferative defects [33],
nor are there any overt phenotypic defects in spermata-
gonial germ cells [34]. Preliminary analysis of human
TEX19 expression indicates it is orthologous to Tex19.1
as it is expressed in human ESCs [29]. Tex19.1 is largely
cytoplasmic and appears to be located in spermatagonial
germline cells of testis seminiferous tubules, with levels
diminishing as cells differentiate during spermatogenesis,
suggesting a germline-specific function [29, 33, 34].
Tex19.1-/- mice are viable with no apparent behavioural
defects [33–35]. There is a slight increase in mortality of
pups older than 5 days post-partum, but this has been
attributed to in utero developmental defects linked to
placental dysfunction [33, 35]. Female fertility of
Tex19.1-/- mice has been independently reported to be
reduced [34] and normal [33], with the discrepancy be-
ing attributed to distinct genetic backgrounds [33].
Males exhibit sub-normal levels of fertility with consider-
able inter-individual differences in spermatogenesis indicat-
ing a phenotypic variability, the cause of which is unknown
[33, 34]. Meiosis in Tex19.1-/- males has defects, which in-
clude impaired meiotic chromosome synapsis, the persist-
ence of unprocessed DNA double-strand breaks, increased
apoptosis and post pachytene meiosis I chromosome segre-
gation defects, although these were not uniformly apparent
[33, 34]. Analysis of gene expression during early spermato-
genesis did not reveal any notable changes to genes that
could directly influence meiosis, but there was significant
elevation in the expression of the class II long terminal re-
peat (LTR)-retrotransposonMMERVK10C [33, 34]. Expres-
sion of other transposable elements (TEs), such as LINEs,
SINEs and IAP retrotransposons did not appear to be al-
tered, indicating TE specific suppressor activity for Tex19.1
in testis, which is proposed to be distinct from the Piwi-
mediated pathway for TE regulation [34].
The proposal that Tex19.1 functions in an independent
TE regulatory pathway is further supported by the finding
that in murine placenta, where there are alterations to ex-
pression levels of some TEs, Tex19.1 is the only known
methylation-sensitive genome defense gene that is highly
expressed [32], suggesting it may independently serve to pro-
tect placental cells from elevated TE expression [35]. Female
Tex19.1-/- mutant mice also exhibit impaired placental func-
tion [33, 35]. Unlike Tex19.1 -/- male testis tissue, Tex19.1-/-
placental tissue exhibits elevated LINE expression and also
exhibits some differential expression of protein coding
genes [35]. Collectively, these findings suggest that Tex19.1
controls transcription/transcript related mechanisms to
protect the germline and placental genomes [29, 33–35].
The finding that human TEX19 is a CT gene opens the
question of whether TEX19 expression is oncogenic or
provides a functional advantage to cancer cells [26, 31].
Expression of germline genes has been linked to poor
patient prognosis in cancers, such as lung cancer (for
example, see [36]), so revealing functional roles of these
genes, if any, is important to understand the mechanisms
of cancer development/progression. In this study we iden-
tify a requirement for TEX19 in human cancer cells to
drive proliferation that reveal it to be a potential cancer-
specific drug target and prognostic indicator.
Methods
Cell culture and proliferation/self-renewal assays
Human cacner cell lines used in this study are provided
in Additional file 1; Table S1. Cells were cultured in
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McCoy’s 5A medium (Thermo Fisher Scientific, Runcorn,
UK) supplemented with 10% fetal bovine serum (FBS; Life
Technologies) or in RPMI medium supplemented with
10% FBS and 2 mM sodium pyruvate (Thermo Fisher
Scientific, Runcorn, UK); SW480 cells were cultured in
Dulbecco’s modified Eagle’s Medium (Thermo Fisher
Scientific, Runcorn, UK).. All cells were cultured at 37 °C
in 5% CO2 in a humidified incubator. All cells were au-
thenticated once every 12 months using LGC Standards
Cell Line Authentication service (last report number:
710236782; Teddington, UK). Cells were regularly checked
for mycoplasma using the LookOut Mycoplama Detection
Kit (Sigma, Irvine, UK).
For leptomycin B (LMB) treatment cells were seeded
into 40 mm tissue culture dishes and grown to the
required density. Cells were then treated with 10 ng/ml
LMB (L2913; Sigma, Irvine, UK) and incubated for a
further 16 h.
Extreme limiting dilution analysis (ELDA) was per-
formed as previously described [37, 38]. Briefly, sphere-
derived cell were collected from 10 cm dishes and diluted
into single cell suspension and plated at concentrations of
1000 to 1 cells per 100 μl SCM using repeats of defined
experimental conditions in 96 well ultra-low attachment
plates (Costar Corning; Sigma, Irvine, UK). Cells were in-
cubated at 37 °C in a 5% CO2 atm for 10 days. Cells were
supplemented with 50 μl of stem cell media (SCM) and
transfection complexes re-applied after 4 and 8 days of in-
cubation. At the end of 10 days the number of wells show-
ing spheres with more than 20 cells were counted by light
microscope. ELDA web tool (hrrp://bioinf.wehi.edu.au/
software/elda) was used to determine frequencies of
sphere forming cells.
Staining for senescence was carried out using β-
galactosidase Staining Kit (Cell Signaling, Leiden, Holland)
following the manufacturer’s instructions.
siRNA transfection
siRNAs used in this study are TEX19 siRNA A (5′-AGGA
TTCACCATAGTCTCTTA-3′), TEX19 siRNA B (5′-TTC
AACATGGAGATCAGCTAA-3′) and a negative con-
trol (Qiagen, Manchester, UK, Allstars Negative Control
siRNA). Transfection was carried out with HiPerFect
(Qiagen, Manchester, UK) following the manufacturer’s in-
structions. Briefly, 150 ng of siRNA was mixed with 6 μl
of HiPerFect and 100 μl of cell specific medium. This mix
was incubated at room temperature for 15 min to permit
transfection complexes to form and was then added in a
dropwise fashion to approximately 1.5 × 105 cells. The
number of siRNA treatments per cell culture was
dependent upon the specific experiment and siRNA was
added to cells at least once every 24 h for proliferation
assays over extended periods. Depletion was verified by
RT-qPCR and/or western blotting.
Whole cell extraction, fractionation and western blotting
Whole-cell lysates were prepared using M-PER lysis
buffer (Thermo Fisher Scientific, Runcorn, UK #78503),
Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific,
Runcorn, UK) and Halt Phosphatase Inhibitor Cocktail
(Thermo Fisher Scientific, Runcorn, UK). Approximately
30 μg of protein extract were used for western blotting
(WB). Samples were mixed with 2X Laemmli Buffer (1:1)
(Sigma, Irvine, UK; S3401) and boiled at 100 °C for 5 min
prior to electrophoresis. Precision Plus Protein Dual Color
Standards (BioRad, Watford, UK) was used as a protein
ladder. NuPAGE Novex 4–12% Bis-Tris gels (Thermo
Fisher Scientific, Runcorn, UK) were used and electro-
phoresis was carried out in NUPAGE MOPS SDS buffer
(Thermo Fisher Scientific, Runcorn, UK) for 90 min at
120 v. Fast Western Blot Kit, ECL substrate (Thermo
Fisher Scientific, Runcorn, UK) was used according to
manufacturer’s instructions to detect the primary anti-
bodies. Membranes were probed with primary antibodies
in 10% dry milk/PBS/0.5% Tween 20. Incubation with sec-
ondary antibodies was performed at room temperature for
1 h, followed by a 10 min wash in milk solution and 3 add-
itional 10 min washes in PBS/0.5% Tween 20 at room
temperature. Antibody detection was performed using
Pierce ECL Plus Western Blotting Substrate (Thermo
Fisher Scientific, Runcorn, UK).
Subcellular fractionation was carried out as follows.
Following harvesting cells were resuspended in hypo-
tonic buffer [50 mM Tris-HCl (pH 7.4), 0.1 M sucrose,
1 mM AEBSF] and lysis buffer C (1% Triton, 10 mM
MgCl2, 1 mM AEBSF) at 1:1 ratio. Following incubation
on ice for 30 min tubes were spun at 6000 g for 2 min.
Supernatant contained cytoplasmic proteins and the pel-
let was resuspended in lysis buffer N [50 mM Tris-HCl
(pH 7.4), 100 mM potassium acetate, 1 mM AEBSF] to
extract nuclear protein.
The following antibodies were used in this study: anti-
TEX19 (R & D Systems, AF6319), 1:200 dilution for
WB; anti-Lamin B1 (Abcam, AB16048), 1:1000 dilution
for WB; anti-tubulin (Sigma, T6074), 1:8000 dilution for
WB; anti-cleaved caspase-3 (Cell Signaling, Leiden,
Holland; 9664), 1:1000 dilution for WB; cell cycle cocktail
(anti-pCDK2, anti-Actin, anti-pH3) (Abcam, Cambridge,
UK; AB136810), 1:250 dilution for WB; anti-rabbit sec-
ondary antibody (Cell Signaling, Leiden, Holland; 7074),
1:3000 dilution for WB; anti-mouse secondary antibody
(Cell Signaling, Leiden, Holland; 7076).
For the chromatin association assay (Ch) protein ly-
sates were prepared consecutively with increased con-
centrations of NaCl. Protein extracts were subjected to
western blotting as described using anti-a-tubulin and
anti-histone H3 antibodies in addition to anti-TEX19
antibodies. 10 ng/ml KaryoMAX colcemid (Gibco, Runcorn,
UK; 15212-012) was added to the growth medium to
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synchronize cells in metaphase prior to chromatin
extraction.
Reverse transcription quantitative polymerase chain
reaction (RT-qPCR)
Total RNA was extracted from appropriate cell cultures
using the RNeasy Plus Mini Kit (Qiagen, Manchester, UK)
following the manufacturer’s instructions. First-strand
cDNA synthesis was carried out using SuperScript III
First-Strand Synthesis System (Thermo Fisher Scientific,
Runcorn, UK) following the manufacturer’s instructions.
qPCR reactions were carried out using GoTaq qPCR
Master Mix (Promega, Southampton, UK) in a CFX96
Real-Time PCR Detection System C100 thermal cycler
(BioRad, Watford, UK). All RT-qPCR primers were
obtained from Qiagen (Manchester, UK). The excep-
tions were the HERV primers and primers for PIWIL3
and PIWIL4. PIWIL3 primers were PIWIL3F (5′-TGG
CATTGCATTAAGTAAGGG-3′) and PIWIL3R (5′-T
TTGAAAAACGCAAACATCG-3′). PIWIL4 primers
were PIWIL4F (5′-CTGAAGGATACAGCGGGAAA-3′)
and PIWIL4R (5′-AAAGATGCACTCAGCAAGGAC-3′).
HERV primers are listed in Additional file 2; Table S2;
other RT-qPCR primers are shown in Additional file 3;
Table S3. Reactions were carried out in triplicate with
PCR primers at a final concentration of 0.2 μM in a final
volume of 25 μl. All PCR primers are available upon re-
quest. BioRad CFX Manager 2.0 software was used to
determine primer efficiency/specificity, threshold cycle
values (Ct values) and expression values using default
parameters. Results were normalized using two or three
reference genes and fold-change values were calculated
based on the ΔΔCT method.
RNA sequencing and data analysis
Total RNA was extracted using RNeasy Plus mini kit
(Qiagen, Manchester, UK) according to the manufac-
turer’s protocol. RNA quality was checked on an Agilent
Bioanalyzer RNA 6000 nano chip and was assessed to be
of high quality (RIN > 9.8). Indexed sequencing libraries
were then prepared using the Illumina TruSeq v2 proto-
col. Briefly, polyA-tailed RNA enriched on oligo-dT
beads before fragmentation and random priming. Re-
verse transcription was carried out with second strand
synthesis and the resultant double-stranded cDNA was
end repaired, A-tailed and Illumina TruSeq adapters
were ligated. Correctly ligated fragments were enriched
by performing 12 cycles of PCR with primers comple-
mentary to the Illumina adapters. The final libraries
were checked and quantified on the Agilent Bioanalyzer
DNA 1000 chip and the Life Technologies Qubit High
Sensitivity DNA assay system before being pooled to an
equimolar concentration of approximately 10 nM. qPCR
was performed on a 105 dilution of the multiplex pool
(Kapa Biosystems Library Quantification Kit; Sigma,
Irvine, UK) before 12 pM of multiplex library was se-
quenced on one lane of an Illumina HiSeq (TruSeq v3
chemistry) generating 190 million reads passing filter.
Reads were demultiplexed and fastq files generated using
Illumina CASAVA v1.8.2 software.
Fastq data underwent guided alignment to the human
genome (NCBI Build 37.2) using Tophat v2.0.6 [39]
with default parameters. Read duplicates were removed
using Picard (http://broadinstitute.github.io/picard) and
counts per gene generated using HTSeq [40]. Differential
expression at both the gene and exon level was carried out
in R (https://www.r-project.org/) using the ‘DESeq’ and
DEXSeq’ R packages [41]. The resulting P values were ad-
justed for multiple testing with Benjamini and Hochberg’s
[42] method to control the false discovery rate. Genes with
a P value <0.05 and a log2-fold change > 1.0 have been se-
lected as significant. Pathway and gene ontology (GO) ana-
lysis was carried out in R v3.2.3 (https://www.r-project.org/)
using the ‘GOstats’ R package [43].
Fluorescence activated cell sorting cell cycle analysis
Following trypsinization cells were fixed in 70% ethanol at
4 °C overnight. Fixed cells were treated with 0.5 mg/ml
RNase A (Sigma, Irvine, UK) and stained with propidium
iodide (500 nM, Sigma, Irvine, UK). Stained cells were
analyzed using a Partec CyFlow Cube 8 and cell cycle ana-
lysis was carried out using FCS Express 4 software.
Immunohistochemistry (IHC) and human tissue
Human tissue was obtained from patients following
the guidelines of the North Wales Research Ethics
Committee – West. All tissues were fixed in formalin,
embedded in paraffin and prepared as 4 mm slices.
Tumour/normal tissue arrays were obtained from the
Cooperative Human Tissue Network (University of
Virginia, USA). Staining was automated using the
Ventana Benchmark XT instrument. Chromogenic re-
actions were carried out using 3,3′-diaminobenzidine
and slides were counter stained with haematoxylin.
The rabbit polyclonal anti-TEX19 antibody (Abcam,
Cambridge, UK; 185507) was used for TEX19 staining.
Secondary antibody only staining was used as a con-
trol. Antigen retrieval consisted of 4 min wash with
protease I. All slides were scanned using and Axio
Scanner.Z1 Scanner (Zeiss Cambridge, UK).
Tissue/cell immunofluorescence imaging
For staining of cultured cells 105 cells were seeded on a
cover slip in a 24-well plate with appropriate medium
and grown to the required density. Cells were fixed in
4% paraformaldehyde in PBS for 10 min at room
temperature and then washed three times with PBS at
room temperature. Cells were incubated for 1 h in 5%
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FBA/0.3% Triton in PBS at room temperature. Cells
were incubated with primary antibodies in 1% BSA/0.3%
Triton in PBS at appropriate concentrations overnight at
4 °C. Following three 5 min washes in PBS appropriate
concentrations of the required secondary antibody were
incubated with the cells in the same buffer for 1 h at
room temperature in the dark. Following final washing
cover slips were mounted on slides with Vectashiled
Hard Set Antifade Mounting Medium (Vector Labora-
tories, Peterborough, UK) and counter stained with
DAPI (Sigma) as required. Images were acquired using a
Zeiss LSM 710 confocal microscope and analyzed using
ZEN software (Zeiss, Cambridge, UK).
For tissue staining 4 μM paraffin embedded section
were deparaffinised and re-hydrated as follows: three
times through xylene, two times through 100% ethanol,
two times through 70% ethanol, two times through ster-
ile distilled H2O. Antigen retrieval was performed by
heating samples in boiling 10 nM sodium citrate buffer
(pH 6.0) for 10 min and cooling slides to room
temperature. Slides were washed in sterile distilled water
and stained as for the cultured cells (see above).
Antibodies used for staining were as follows, anti-TEX19
(Abcam, Cambridge, UK; AB185507), dilution of 1:50; anti-
MAGE-A1 (LSBio, Nottingham, UK; LS-C87868), dilution
of 1:20; anti-vimentin (LSBio, Nottingham, UK; LS-B7191),
dilution of 1:100; secondary goat anti-rabbit (Alexa Fluor
488; Thermo Fisher Scientific, Runcorn, UK; A11034),
dilution of 1:1,1000; secondary goat anti-mouse (Alexa
Fluor 568; Thermo Fisher Scientific, Runcorn, UK; A11031),
dilution of 1:1000.
Mouse tumourgenicity assay
In vivo tumour growth capability of Tex19shRNA-
SW480-c3 cells was assessed by sub-cutaneous xenograft
into immune deficient NSG mice (Envigo, Derby, UK).
Cells were harvested using 1 mM EDTA and re-
suspended at a density of 5 × 107 cells/ml in serum free
DMEM medium. A total of 5 × 106 cells were injected
sub-cutaneously into the flank of each mouse. Cells were
allowed to establish for 6 days prior to induction of
shRNA expression with doxycycline. To induce shRNA
expression, mice were injected with 10 mg/kg intra-
peritoneally every 2 days. Mice were then monitored, and
when palpable, tumour volume was measured twice weekly
with a digital caliper. Relative tumour volume (RTV) was
calculated using xy2/2; where x is the longest axis of the
tumour and y is the shortest axis of the tumour.
Survival analysis
Cancer data sets available from The Cancer Genome
Atlas (TCGA; http://cancergenome.nih.gov) were analyzed
using R v3.2.3 (https://www.r-project.org/) to assess
the association of TEX19 expression and clinical data.
Normalized gene RSEM values for all TCGA RNA-seq
data sets as well as corresponding clinical data were
downloaded from http://firebrowse.org. The survival
analysis was carried out on primary tumour samples
apart from leukaemia, where the primary blood de-
rived cancer samples from peripheral blood were used.
Normalized RSEM values were transformed to log2
counts per million prior to survival analysis using voom
[44] in the ‘limma’ R package [45]. The patients were cate-
gorized in to two groups, low and high TEX19 expression
in cancer, split by the median value. Overall survival (in
years) related to TEX19 expression was computed with
the Kaplan-Meier method and compared by the log rank
test using the ‘survival’ R package [46]. P values of <0.05
were considered statistically significant.
Results
TEX19 is required for the proliferation and self-renewal of
human cancer cells
Given the finding that TEX19 is expressed in a range of
cancers (http://cancergenome.nih.gov/) [26] and the
finding that other CT genes play a role in oncogenesis
(for example, see [13]), we set out to determine whether
TEX19 contributes to proliferative potential of human
cancer cells. We chose colon cancer cell line SW480 as
our primary model system as these cells are enriched for
cancer-stem-like cells. Other cells lines previously shown
to express TEX19 [26], including an additional colon line
(HCT116) as well as a lung cancer line (H460) and an
embryonal cancer line (NTERA2), were also employed
to assess potential universality of proliferative and/or
functional role(s) for TEX19. In these cell lines siRNA-
depletion of TEX19 (using independent siRNAs) results
in an inhibition of proliferation (Fig. 1a; Additional file
4: Figure S1a-d; siRNA-mediated TEX19 depletion was
confirmed by RT-qPCR and western blotting, examples
given in Fig. 1a; Additional file 4: Figure S1; western
blots also validate the anti-TEX19 antibody).
TEX19 expression is found in germ cells/ESCs, and
murine Tex19.1 has been linked to ESC self-renewal
[33]. To determine whether human TEX19 functions in
self-renewal in cancer stem/progenitor cells, we carried
out extreme limiting dilution assays (ELDA) to deter-
mine self-renewal ability in sphere-derived SW480 cells
and NTERA2 cells [37]. Cultures treated with inde-
pendent siRNAs had reduced sphere formation from
single cells (Fig. 1b; Additional file 5: Figure S2). This
demonstrates that TEX19 is required for proliferation/
self-renewal of cancer cells, which could infer such a
role in germ and stem cells. Over expression of TEX19 in
SW480 cells using a doxycycline inducible TEX19 did not
further accelerate proliferation (Additional file 6: Figure
S3), suggesting the requirement for TEX19 may have an
upper threshold.
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To determine whether TEX19 plays a role in self-
renewal/proliferation in tumours in vivo we developed
SW480 and HCT116 cell lines carrying an inducible
shRNA cassette. A clone (TEX19shRNA-SW480-c3) was
selected and proliferation analysis with and without
doxycycline (dox) was carried out (expressing and not
expressing TEX19shRNA). Induction of the shRNA
resulted in a moderate, but statistically significant reduc-
tion in proliferation (Fig. 1c). A similar proliferative
inhibition was observed with shRNA induction in
HCT116 (Additional file 7: Figure S4). The inducible-
shRNA SW480 cells were injected subcutaneously into
NSG mice. One cohort was injected with dox, whereas a
control population was not. Despite the relatively mild
proliferative reduction observed in vitro, TEX19-shRNA
induction in mice resulted in significant reduction of
tumour volume, indicating that TEX19 expression is re-
quired for tumour development (Fig. 1d).
To gain insight into the role that TEX19 plays, we
assessed various parameters of cells depleted for TEX19.
Whilst proliferation of SW480 cells is inhibited following
TEX19-depletion, the cells do not stain with trypan blue,
suggesting that they retain viability, at least in the short-
medium term. We next tested whether these cells become
apoptotic. This was assessed by western blot analysis of
cleaved caspase-3, a marker of the caspase-dependent
apoptotic programme. No measurable level of cleaved
caspase-3 was detected (Fig. 2a), consistent with murine
Tex19.1-/- ESCs [33]. Taken together these two observa-
tions indicate that TEX19-depleted cells remain viable
and, unlike murine Tex19.1 -/- spermatocytes, are not
undergoing measurable programmed cell death [33, 34].
Next we tested siRNA treated cells from the ELDA with
β-galactosidase, a measure of lysosome-dependent senes-
cence. No measurable staining was observed, indicating
these cells do not appear to be senescent (Fig. 2b). How-
ever, when TEX19-siRNA treated cells that failed to prolif-
erate were washed and placed in siRNA-free fresh media,
they did not re-initiate proliferation, suggesting that they
have entered a non-senescent, non-apoptotic state from
which they cannot readily recover, possibly a quiescent-
like state.
To assess the cell cycle status of TEX19-depleted cells
we analysed DNA content using FACS (Fig. 2c, d). The
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Fig. 1 TEX19 is required for cancer cell proliferation and self-renewal: a Left hand line plot: siRNA-mediated (siRNA A) TEX19 mRNA depletion results in
inhibition of SW480 cancer cell proliferation (*≤ 0.05; unpaired t-test); right hand bar chart: RT-qPCR analysis of TEX19 mRNA levels for the cell cultures
shown in the adjacent cell count plot (**≤ 0.01; unpaired t-test; siRNA treatment occurred every 24 h and RNA extraction for RT-qPCR was taken 24 h
following final siRNA treatment). b Extreme limiting dilution assay shows that TEX19 siRNA treatment (siRNA A) results in loss of self-renewal capacity in
SW480 cancer cells (***≤ 0.001; chi square test). Sphere formation was monitored following 10 days incubation. c Left hand line plot: shRNA-mediated
(+dox) TEX19 mRNA depletion results in reduction in proliferative potential of SW480 cancer cells (*≤ 0.05; unpaired t-test; RNA extraction for RT-qPCR
was taken 24 h following final Dox treatment); right hand bar chart: RT-qPCR analysis of TEX19 mRNA levels for cell cultures shown in the adjacent plot
(*≤ 0.05; unpaired t-test). d Left hand line plot: SW480 cell carrying a dox-inducible shRNA cassette generate tumours with reduced volume when the
mice are fed with dox (red line) compared with no dox (grey line). P value is derived from a Wilcoxon matched pairs test (2-tailed); right hand bar chart:
RT-qPCR analysis of TEX19 mRNA levels within final tumours extracted from mice used in the experimental set shown in the adjacent line plot
(*≤ 0.05; unpaired t-test: RNA was extracted for RT-qPCR analysis immediately following termination and tumour extraction for both +/- Dox)
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percentage of cells with a 2C compliment (G1) appears
to remain unaltered. However, more cells accrue in S-phase
and there are fewer cells with a full 4C compliment (G2) in-
dicating that TEX19-depleted cells appear to have a delay
in S-phase progression, albeit limited. We employed west-
ern blots on whole cell extracts of TEX19-depleted cells
using antibodies to assess cell cycle progression [anti-pho-
pho CDK2 Tyr15 (G1-S transition), anti-phopho histone
H3 Ser10 (mitosis), anti-actin (loading control)] (Fig. 2e).
There was no notable change in phospho-CDK2, support-
ing the FACS data, which indicate these cells progress
normally into S-phase. There is an apparent reduction
in the levels of phopho-histone H3 indicating there are
fewer cells entering mitosis, again, consistent with the
FACS profile which shows a limited delay in S-phase
progression/completion. Collectively, these data indi-
cate that whilst TEX19-depleted cells are viable (in the
short-term, at least), the inhibition of proliferation might
be linked to a delayed progression through S-phase which
does not trigger apoptosis or senescence.
TEX19 is present is both the nucleus and the cytoplasm
of human cancer cells
To gain insight into the possible function(s) of TEX19 in
cancer cells, we assessed cellular localization. Previous
studies on murine cells have reported a predominantly
cytoplasmic localization for Tex19.1 [33, 34], but with some
nuclear Tex19.1 in placental cells [35]. Immunostaining of
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Fig. 2 Analysis of TEX19 depleted SW480 cells: a TEX19 depleted SW480 cells do not have cleaved caspase-3 indicting there is no measurable
apoptosis. b TEX19 depleted SW480 cells (lower image) do not form full spheres and exhibit no staining with β-galactosidase indicating that they
are not undergoing lysosome-dependent senescence (upper image shows SW480 spheres in the absence of TEX19 siRNA staining positive for
β-galactosidase due to natural senescence of internal cells; bar = 250 μm). c FACS of TEX19 siRNA treated SW480 cell populations (a minimum of
10,000 cells were analyzed in each case). d TEX19 siRNA treated cells have a lower proportion of the population in G2 and a higher proportion in
S phase. e Western blot of whole cell extracts of SW480 cells depleted for TEX19 have lower levels of phosphor-histone H3 indicating fewer cells
in mitosis. f Western blot and RT-qPCR analysis demonstrating TEX19 depletion (for data shown in a and c-e)
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TEX19 in sub-confluent SW480 cells showed TEX19 lo-
cated in both the cytoplasm and the nucleus, with some
cells having a stronger nuclear staining than others (Fig. 3a).
To further verify that there was a nuclear fraction of
TEX19, we carried out western blots on nuclear and cyto-
plasmic extracts, which demonstrated that the majority of
TEX19 is cytoplasmic in sub-confluent SW480 cells, but
there is a measurable amount of TEX19 in the nucleus
(Fig. 3b). To further verify the finding that some TEX19 is
nuclear, we treated SW480 cells with leptomycin B (LMB),
an inhibitor of the CRM1-dependent nuclear export path-
way. LMB treated cells have a clear accumulation of TEX19
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Fig. 3 TEX19 has nuclear and cytoplasmic localization in cancer cells: a Sub-confluent SW480 cells show TEX19 (red) localized to both nucleus and
cytoplasm. Distinct cells show distinct proportions of cellular TEX19 within the nucleus. DNA is stained with DAPI (blue); bar = 40 μm. b Western blot
analysis of nuclear and cytoplasmic extracts of sub-confluent SW480 cells indicates the majority of TEX19 is cytoplasmic, but a clear nuclear fraction is
detected. Lamin (nucleus) and tubulin (cytoplasm) are used as controls (controls show clean faction signals, indicating no inter-fraction contamination).
c Sub-confluent SW480 cells treated with the nuclear export blocking agent LMB demonstrates that TEX19 (red) can accumulate in the nucleus. DNA is
stained by DAPI (blue); bar = 20 μm. d Western blot analysis of chromatin associated TEX19 demonstrates that TEX19 does not have a tight association
with chromatin, even when cells are blocked in M phase with colcemid. Histone H3 is a control for tight chromatin association (only dissociated with
1.0 M NaCl); tubulin is mostly cytoplasmic (see b) and does not associate with chromatin during the chromatin preparation. e TEX19 is predominantly
cytoplasmic at higher cell densities. Staining of sub-confluent HCT116 cells (top panels) indicates that TEX19 (red; blue =DAPI) is nuclear and cytoplasmic
at this cell density, as for SW480 cells. When cells reach confluence (lower panels) the majority of TEX19 is cytoplasmic. Bar = 20 μm. f When SW480 cells
are densely associated in spheres TEX19 (red; DAPI = blue) is mostly cytoplasmic. Bar = 100 μm. NTERA2 cells show strong nuclear staining with anti-TEX19
antibodies (green) irrespective of level of confluence. Red = anti-tubulin; Blue =DAPI; bar = 20 μm. g NTERA2 cells exhibit predominantly nuclear TEX19.
Green = anti-TEX19; Blue =DAPI; Red = anti-tubulin; bar = 20 μm
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in the nucleus (Fig. 3c). Interestingly, the nuclear TEX19 in
LMB treated cells forms clear foci, potentially indicating
that TEX19 is forming region-specific complexes within
the nucleus. These foci are consistent with chromatin asso-
ciation, so we isolated chromatin from sub-confluent
SW480 cells and treated it with increasing concentrations
of salt. TEX19 dissociated from the chromatin fraction at
low salt concentrations indicating it does not have a strong
association with chromatin (under these conditions; Fig. 3d).
To determine whether nuclear localization of TEX19 is a
common feature of cancer cells, we stained a second cell
line, H460 (lung carcinoma). As for SW480 cells, sub-
confluent H460 cells have nuclear and cytoplasmic TEX19
(Fig. 3e). We noticed, however, when cells were grown to
over-confluence that TEX19 becomes excluded from the
nucleus and appears to be solely cytoplasmic (Fig. 3e). To
expand this observation, we grew colonospheres from
SW480 cells, which are enriched for cancer stem-like cells
[38], and assessed TEX19 localization. In these spheres,
where cells are in close contact, TEX19 is predominantly
cytoplasmic (Fig. 3f), consistent with the majority of
Tex19.1 in murine tissue [33, 34]. Remarkably, in the germ-
line tumour cell line, NTERA2, anti-TEX19 staining is pre-
dominantly nuclear (Fig. 3g), which could infer a link to
germline/stem capabilities for TEX19.
TEX19 localization in human testis and cancer tissues
Our finding that human cancer cells have both nuclear/
cytoplasmic TEX19, led us to investigate the localization
in human cancerous tissues. Previous analysis of human
TEX19 by immunohistochemistry (IHC) demonstrated
that it is not present in normal healthy non-testis tissues,
however, analysis of human testes lead to the proposal that
TEX19 was located in seminiferous tubule Sertoli cells
[31]. This, seems to be in conflict with a direct role for
TEX19 in germ cells / stem cells. To explore this further
we used immunofluorescence to co-stain human testes
with anti-TEX19 and anti-vimentin antibodies; (vimentin
is a Sertoli cell marker). TEX19 staining is located to the
basal layer, which mostly consists of spermatagonial cells
and basal sections of Sertoli cells (Fig. 4a) [47], indicating
that TEX19 staining is in specific cells or specific sub-
cellular regions. Co-staining with an anti-vimentin anti-
body reveals that the high intensity TEX19 staining, whist
in close proximity to the vimentin stain, does not directly
co-localize (Fig. 4a), possibly indicating that TEX19 is
present in a sub-compartment of Sertoli cells or in cells
closely associated with Sertoli cells. There does, however,
appear to be a low intensity TEX19 staining that that is
quite extensive throughout the basal regions, including
Sertoli cells, suggesting distinct TEX19 positive regions
within the basal areas of seminiferous tubules. Whilst
localization was mostly cytoplasmic, we observed foci
within large nuclei of cells located within the basal layer of
a
b
c
d
e
f
DAPI
TEX19 Merged
Vimentin
MAGE-A1 TEX19DAPI Merged
Fig. 4 TEX19 is predominantly localized to the cytoplasm in normal
testis and cancer tissues: a Staining of a human testicular seminiferous
tubule indicates that TEX19 (red – bottom left panel) is predominantly
located in the basal layer of cells and is mostly cytoplasmic. Co-staining
with an anti-vimentin antibody (green – top right), which marks Sertoli
cells, reveals that TEX19 staining is adjacent to, but not overlapping with
vimentin. Bar = 50 μm. b Nuclear foci are apparent when testis are
stained with anti-TEX19 (red; blue = DAPI) antibody. White arrows in the
merged image show the localization of the nuclear staining with anti-
TEX19 antibodies (red; DAPI = blue). c Co-staining with anti-MAGE-A1
antibodies (spermatogonial cells; green) and anti-TEX19 antibodies
(red; blue = DAPI) indicate that TEX19 nuclear foci are associated
with spermatagonia. White arrows indicate anti-TEX19 stained nuclear
foci. Bar = 10 μm. d Staining of clear margin morphologically normal
colon tissue taken from a cancer patient indicates that there is no
staining with anti-TEX19 antibody (red; right hand panel; blue = DAPI,
left hand panel). Bar = 100 μm. e Staining of matched (to tissue shown
in D) colon tumour material shows regions of intense staining with
anti-TEX19 antibodies (red; blue = DAPI). Bar = 100 μm. f Enlargement
of the colon cancer region of intense anti-TEX19 signal (white box; scale
bar is 30 μm) shows that anti-TEX19 staining (red) is mostly cytoplasmic
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the tubules, possibly spermatagonia (Fig. 4b). Spermatago-
nia express MAGE genes (known CT genes), so we co-
stained tubules with anti-MAGE-A1 antibodies. This
appears to show TEX19 foci only within the nuclei of
MAGE-A1 positive cells (Fig. 4c). This indicates that
there are distinct cellular and sub-cellular TEX19 frac-
tions within the testis, consistent with cancer cells.
We next determined the subcellular localization of
TEX19 in cancerous tissue. We used colon cancer tis-
sue and matched histologically non-cancerous adjacent
tissue [48]. Immunofluorescence revealed that adjacent,
clear margin tissue with a morphologically normal ap-
pearance did not stain positive for TEX19 (Fig. 4d). The
cancerous tissue, however, had regions of strong TEX19
staining (Fig. 4f) demonstrating that TEX19 encodes an
antigen within colorectal cancer tissue. Cancerous tissue
has heterogeneous regions that have high levels of TEX19
or none/low levels of TEX19, which fits with emerging
models of tumour heterogeneity [49, 50]. The regions of
intense TEX19 staining reveal that staining appears to be
mostly cytoplasmic (Fig. 4f), consistent with highly conflu-
ent cancer cells and the majority of closely associated cells
within colonospheres (Fig. 3). We cannot, however, ex-
clude the possibility of low levels of nuclear TEX19 in
these cells and we did observe occasional TEX19 foci
associated with DAPI stained nuclear material in the
tumour tissue (Fig. 4f).
TEX19 is associated with early adenoma stages of
colorectal cancer development
To determine the stage of tumour progression at which
TEX19 becomes apparent, we used IHC to stain colorec-
tal cancer progression arrays (Fig. 5a). We analysed
seven independent colorectal tumour progression arrays.
TEX19 was present in all arrays with highest staining
observed in the early adenomas (<2 cm), with different
levels present in later stage disease tissues (Fig. 5b). This
observation indicates that in colorectal cancer develop-
ment TEX19 is present at an early stage in all array
series tested, potentially suggesting a requirement for
TEX19 at an early phase.
TEX19 regulates distinct transposable element transcripts
in a cell-specific fashion
Previously, it has been demonstrated that murine Tex19.1
represses transcript levels from some endogenous retrovi-
ruses (e.g., MMERVK10C) during spermatogenesis, but
not other TE transcripts (including LINEs, SINEs and
other endogenous retro elements), suggesting that it can
differentially regulate TE transcript levels. In contrast, in
Tex19.1-/- murine placental tissue, where Tex19.1 regu-
lates intra-uterine growth, distinct TEs, such as LINEs are
up-regulated, whereas expression of the endogenous
retrovirus MMERVK10C, which is repressed by Tex19.1
during spermatogenesis, remains unaltered [34, 35]. Mur-
ine Tex19.1-/- ESCs exhibit yet another pattern of TE
expression, with up-regulation of MMERVK10C and other
TEs, such as LINE-1 [33]. These findings indicate that
whilst Tex19.1 regulates TE transcript levels in the mouse,
there is heterogeneity that might reflect a tissue or cell
type distinction in Tex19.1 function.
TE activation occurs during oncogenesis [51, 52]. Given
that human TEX19 might regulate progression through S-
phase (see above), and the role for murine Tex19.1 in TE
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Fig. 5 TEX19 is associated with early adenoma stage of colorectal
cancer: a IHC showing an example of a colorectal cancer tissue
progression array stained with anti-TEX19 antibody. BNC = non-
neoplastic colonic mucosa from pre-cancer case; BC = non-neoplastic
colonic mucosa from cancer case; BI = inflamed non-neoplastic
mucosa; AS = colonic adenoma, < 2 cm in diameter; AL = colonic
adenoma, > 2 cm in diameter; CE = invasive adenocarcinoma, stage
T1/T2; CL = invasive adenocarcinoma, stage T3/T4; LN = colorectal
adenocarcinoma metastatic to lymph node; M = colorectal
adenocarcinoma metastatic to distant sites. 10 X magnification used
for all images shown. b Analysis of seven independent colorectal
cancer tissue progression arrays stained with anti-TEX19 antibody.
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3 = strong staining; 4 = very strong staining
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control, it is not unreasonable to postulate that elevated
transposition or TE expression caused by depletion of
TEX19 might retard S-phase. Given this, we used RT-
qPCR to determine whether depletion of TEX19 resulted
in alteration in TE RNA levels in SW480 cells. As for
murine spermatogenesis, we found no change in LINE or
SINE transcript levels. We did, however, find that some
HERVK transcripts were altered; unexpectedly, some were
down-regulated (e.g., HERVK pro), but HERVK HML2
rec was up-regulated (Fig. 6a). This demonstrates that
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Fig. 6 Differential TEX19-assocaited control of TE and piRNA regulatory genes in distinct human cancer cell lines: a RT-qPCR analysis of HERV
genes in SW480 cells depleted for TEX19 mRNA indicates that TEX19 regulates HERV gene expression. b RT-qPCR analysis of expression of piRNA
regulator genes (PIWIL1-4) in three cancer cell lines (A2780, H460, SW480) depleted for TEX19 mRNA indicates that whilst TEX19 controls some,
but not all piRNA genes (PIWIL1-3) in SW480, this is not a universal feature of TEX19 in all cancer cell lines. c RT-qPCR analysis of HERV genes in
SW480 cancer cells depleted for PIWIL1 mRNA indicates that PIWIL1 regulates HERV gene expression. d RT-qPCR analysis of SW480 cancer cells
depleted for both TEX19 and PIWIL1 mRNA demonstrates that TEX19 regulates HERV gene expression in SW480 cells via a PIWIL1-dependent
pathway. e RT-qPCR analysis of mRNA extracts from a range of cancer lines indicates that unlike TEX19, expression of PIWIL1 is not universal in
these cancer cell lines indicating that a functional link between TEX19 and PIWIL1 is not universal. f RT-qPCR analysis of HERV gag gene in seven
cancer cell lines depleted for TEX19 mRNA (+/- siRNA = +/- TEX19 siRNA). g RT-qPCR analysis of HERV rec gene in seven cancer cell lines depleted
for TEX19 mRNA (+/- siRNA = +/- TEX19 siRNA)
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human TEX19 differentially controls HERVK transcripts
in SW480 cells. The reduction in some transcripts was a
little unexpected as murine Tex19.1 appears to function in
TE transcript suppression [34]. Given that we saw reduc-
tions in transcripts, and given the fact that murine
Tex19.1 also controls expression of protein encoding
genes in the placenta, we questioned whether reduction of
human TEX19 might activate the human PIWI pathway,
which may then reduce some HERVK transcripts. To as-
sess this, we determined expression levels of human PIWI
orthologues (PIWIL1-4). All four were expressed in
SW480 cells and PIWIL1-3 are up-regulated following
TEX19 depletion (Fig. 6b; PIWIL4 was not).
To test whether PIWI pathway activation could reduce
levels of some HERVK transcripts, we carried out single
and double gene siRNA depletion of TEX19 and PIWIL1
in SW480 cells. Depletion of PIWIL1 alone results in
both an elevation and a reduction of HERVK transcripts
(Fig. 6c), indicating a differential suppression and acti-
vation role for PIWIL1. Remarkably, co-depletion of
PIWIL1 and TEX19 results in no measurable change to
HERVK transcript levels, suggesting that the HERVK
transcript level changes following depletion of TEX19
in SW480 cells could be PIWIL1-dependent (Fig. 6d).
However, if this was simply due to PIWIL1 acting down-
stream of TEX19, co-depletion of TEX19 and PIWIL1
should result in a PIWIL1-difficient phenotype (e.g., eleva-
tion of HERVK pro transcripts), which is not the case.
Alternatively, this points to a more complex interplay be-
tween TEX19 and PIWIL1 in SW480 cancer cells, possibly
indicating that TEX19 and PIWIL1 have opposing and in-
dependent roles in regulating TE transcripts (for example,
TEX19 positively regulates HERVK pro, whereas PIWIL1
negatively regulates HERVK pro transcripts). This model is
supported by the observation that HERVK gag transcripts
(for example) are reduced following TEX19 depletion in
H460 cells, which do not exhibit measurable expression of
PIWIL1 (Fig. 6d). A model in which TEX19 functions inde-
pendently of PIWI pathway proteins is consistent with ob-
servations in the mouse [34].
To assess the universality of this phenomenon, we ex-
plored PIWIL1 expression in other cell lines (Fig. 6e).
We could detect no expression in A2780, H460,
HCT116 or HeLaS3 cells and virtually no expression in
PEO14. In two of the negative lines, H460 and A2780,
we analysed the expression of the other PIWI paralo-
gues. We could detect no expression of paralogues in
H460, with A2780 expressing PIWIL2 and relatively low
levels of PIWIL4; however, the levels of neither were
significantly altered by TEX19 depletion, suggesting that
TEX19 regulation of PIWI gene expression may not be
universal in all cancer cell types (Fig. 6b).
We next addressed whether TEX19 influenced tran-
scriptional activation of HERV genes in other cell lines,
including H460 where no PIWI paralogues were expressed.
These analyses indicate that there are some changes (for
example, see Fig. 6f, g). For example, A2780 shows consid-
erable activation of HERVK gag transcripts in response to a
relatively modest depletion of TEX19 (Fig. 6f).
TEX19 regulates protein coding gene transcript levels
To explore the possibility that TEX19 acts as a protein
coding gene transcriptional regulator in cancer cells, we
carried out RNA sequencing on total polyA-RNA ex-
tracted from untreated SW480 cells and cells treated
with aTEX19 siRNA. Transcript levels from 80 genes were
found to be significantly (P < 0.05) altered (up-/down-reg-
ulated), including a reduction in TEX19 mRNA, as ex-
pected, and an increase in PIWIL1 mRNA, consistent with
our RT-qPCR (Additional file 8; Figure S5). Of the 80
genes, some are known CT genes; for example, we previ-
ously reported SEPT12 and RAD21L1 as CT genes [26], so
these genes require TEX19 to control their expression in
SW480 cells. Given that we found that PIWIL1 expression
regulation is not uniform in all cell lines, we carried out
RT-qPCR for 52 of these genes (those with an RNA-seq P
value of <0.01; Additional file 3; Table S3) in additional
cell lines (H460, A2780, PEO14, NTERA2, and an inde-
pendent duplicate analysis of SW480). No genes exhibited
consistent changes across all cells lines (Additional file 3;
Table S3), and distinct analysis of SW480 gave some in-
consistencies suggesting a variability due to TEX19 dose
(independent siRNA depletion of TEX19 is unlikely to
have been uniform in all experiments). However, many
gene transcripts did exhibit changes (up or down) indicat-
ing that TEX19 can regulate transcript levels of protein
coding genes, possibly in a TEX19 dose-dependent fash-
ion. Some of the genes, for example, TSN and MYB, are
potential regulators of proliferation [53–57] and so this
could indicate that TEX19 is required by cancer cells to
drive proliferation by maintaining sufficient levels of onco-
genic transcripts.
High TEX19 expression is a prognostic marker in a range
of cancer types
Expression of germline genes has previously been re-
ported to be linked to poor prognosis in cancers, for
example, lung cancer (for example, see [36]). Given the
finding that TEX19 controls cancer cell proliferation we
wished to explore whether TEX19 expression influences
clinical progression. We used RNA-seq data from TCGA
to determine whether high levels of TEX19 expression
were linked to poor prognosis. For each cohort of cancer
patients we divided the population into high and low
TEX19 expression groups split by the median value and
performed survival analysis. 37 data sets for distinct
cancer groups were available, of which 27 held sufficient
data for analysis (TCGA; Additional file 9; Table S4).
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High TEX19 expression (as split by the median) is sig-
nificantly linked to overall survival in seven data sets.
For breast invasive carcinoma (BRCA; Fig. 7a), prostate
adenocarcinoma (PRAD; Fig. 7b) and the pan-kidney
cohort (KIPAN; Fig. 7c) high TEX19 expression is asso-
ciated with poor prognosis; although the difference is
marginal for PRAD. The KIPAN data set consists of data
from three distinct renal cancer data sets (kidney chro-
mophobe – KICH, kidney renal clear cell carcinoma –
KIRC, kidney renal cell carcinoma – KIRP). Analysis of
two independent kidney cancer data sets (KIRK and
KIRP) reveals that both show significant reductions of
overall survival for the higher TEX19 expression cohort
of patients (Additional file 10: Figure S6a/b); KICH is a
rare renal cancer, only contributing to approximately 5%
of all renal cancers [58], and it has a better prognosis
than more common forms of renal cancer [59], so lim-
ited data excluded it from individual analysis.
Intriguingly, higher TEX19 expression is linked to a
better prognosis for gliomas (GBMLGG; Fig. 7d) and brain
lower grade glioma (LGG; Additional file 10: Figure S6c).
This finding was unexpected as previous studies have
indicated germ line gene expression is linked to a poor
prognosis.
The use of a single criteria for the cohort split point,
such as splitting by the median, limits analyses of this
nature. Use of other split points resulted in additional
cancer types showing TEX19 expression linked to prog-
nosis; two examples are the data sets for lung adenocar-
cinoma (LUAD) and cervical squamous cell carcinoma/
endocervical adenocarcinoma (CESC) when patients are
split into the upper 25% of TEX19 expression vs. the
lower 75% expression for cancers where clinical data are
available, where a significant (P = 0.039 and P = 0.038
respectively) link to poor prognosis is observed [which is
not significant (P = 0.136 and P = 0.236 respectively)
when the split is by the standard method of the median]
(Additional file 11; Figure S7). Increased data volume
and further sub-categorization of tumour types is likely
to further resolve which cancer types can be stratified by
TEX19 expression profiling, but these initial findings
clearly indicate that TEX19 expression is linked to
distinct clinical outcomes. In many of the cell line exper-
iments we conducted we used colon cancer cells, yet
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Fig. 7 TEX19 expression is linked to cancer prognosis: a Kaplan-Meier (KM) plot showing overall survival (OS) for breast cancer patient cohort
(BRCA) indicates that higher TEX19 expression is linked to a poor prognosis. Populations are divided by median TEX19 expression (red = high;
grey = low). Dashed lines are 95% confidence intervals. b KM plot visualizing OS for a pan-kidney (KIPAN) cancer patient cohort indicates that high
TEX19 expression is linked to a poor prognosis. Populations are divided by median TEX19 expression (red = high; grey = low). Dashed lines are
95% confidence intervals. c KM plot showing OS for a prostate (PRAD) cancer patient cohort indicates that high TEX19 expression is linked to a
poor prognosis. Populations are divided by median TEX19 expression (red = high; grey = low). Dashed lines are 95% confidence intervals. d KM
plot visualizing OS for a glioma (GBMLGG) cancer patient cohort indicates that high TEX19 expression is linked to a better prognosis. Populations
are divided by median TEX19 expression (red = high; grey = low). Dashed lines are 95% confidence intervals
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interestingly, none of the splits we allocated to colorectal
cancer data (263 patients; 124 expressing TEX19 at the
threshold set for positive expression) indicated a link to
prognosis. There could be number of reasons for this,
not least of which is the heterogeneous nature of TEX19
distribution to distinct tumour regions in the colon
tumour samples we analysed (i.e. the RNA-seq data may
have been obtained from tumour biopsy regions that
may have had limited/no TEX19 expression); given this,
we cannot rule out a link between TEX19 expression
and cancer progression for colorectal cancers. The dis-
tinct link of high TEX19 expression to positive and nega-
tive prognosis is discussed further below.
Discussion
The idea that cancer cells achieve self-renewal potential
by re-activating programmes that regulate the germ/stem
like state, and undergo a soma-to-germline transition is
gaining traction (for example, see [2, 3, 5]). Germline func-
tions are known to contribute to distinct biological features
of cancers [11–13], including invasiveness/metastasis (for
example, [21–23, 25]) and maintenance of proliferative
potential (for example, [14–19]). Some activities are linked
to poor outcomes; for example, elevated expression of
SPANX-A/C/D is linked to poor prognosis in breast cancers
[25]. Furthermore, germline gene expression in lung cancer
has been linked with aggressive, metastases prone disease
and can be used for stratification of patients to identify co-
horts who might benefit from targeted therapies [36]. Even
meiotic chromosome regulators have been shown to
contribute to oncogenesis by driving inter chromosomal
associations required for oncogenic alternative lengthen-
ing of telomeres [60]. So, germline/stem cell factors can
make distinct contributions to cancer progression, main-
tenance and evolution.
TEX19 as an oncogenic driver
Despite the growing evidence for the soma-to-germline
transition of tumours, the reported roles of specific
germline genes in cancers remains limited. Here we find
that TEX19 expression is required to maintain the prolif-
erative potential of a range of different cancer cells.
Given that TEX19 is expressed in many cancer types,
this might infer that it is an oncogenic factor, indeed, all
cell lines / tumour samples we analysed showed evi-
dence of TEX19 expression. This is not the case for all
database studies [for example, the Human Protein Atlas
(www.proteinatlas.org) reports only limited TEX19
expression], but we have demonstrated that some areas
of later stage tumours are more prone to TEX19 expres-
sion, suggesting that expression can be regional within
an advanced tumour. It is known that tumours can
evolve and acquire a high degree of intra- and inter-
tumour heterogeneity, and so database samples may also
include information acquired from tumour regions that
do not express TEX19 [49, 50]. The heterogeneous dis-
tribution of TEX19 indicates two possibilities; firstly,
TEX19 may be ‘on’ during the early stages of tumouri-
genesis and becomes deactivated during the evolution of
the tumour, or, alternatively, TEX19 only becomes acti-
vated in specific regions as the tumour develops and
grows. The finding that germline genes are actually
required for the early oncogenic process in D. melanoga-
ster l(3)mbt tumours might suggest the former is the
case [7]. Our analysis of colorectal tumour progression
profiles (Fig. 5) supports this view, as TEX19 was de-
tected in all early adenomas, but was not detected in
some samples of later stages of tumour progression
which could point to an early ‘on’ later ‘off ’ model for
TEX19. This suggests that therapeutic targeting of
TEX19 might not eliminate all tumour cells in later
stage tumours. However, given the fact that TEX19 func-
tion is implicated in stemness [29], it might be the case
that the TEX19 positive cells are those that retain stem-
like features and thus therapeutic targeting of these cells
remains important, as these cells might be driving the
poor prognosis/therapeutic resistance [1].
How does TEX19 modulate proliferation?
We have demonstrated that TEX19 expression is re-
quired to maintain proliferation/self-renewal in a range
of cancer cell types. Loss of murine Tex19.1 can result
in spermatogenic cells entering apoptosis, however,
analysis of TEX19-depleted human cancer cells indi-
cates that they are likely to be in a quiescent-like state,
which appears to be linked to a failure to proceed
through S-phase with normal kinetics. This observation
is in contrast to murine Tex19.1-/- ESCs, which, whilst
being defective in self-renewal, do not exhibit any overt
S-phase defects [33]. Murine Tex19.1 has been shown
to control levels of TE transcripts and, in the case of the
female placenta, other protein coding transcripts [35]. We
have demonstrated here that TEX19 in SW480 cells can
influence TE transcript levels. In SW480 cells this appears
to be counteracted by a PIWIL1-dependent mechanism. A
model in which TEX19 and PIWIL1 serve in opposing
and independent mechanisms for TE transcript control is
consistent with murine Tex19.1 acting on TEs in a PIWI-
independent fashion [34]. Indeed, in other cancer cells
lines we tested PIWIL1 is not expressed and yet TE
transcripts exhibit a measurable change upon TEX19
depletion, which supports a TEX19-dependent, PIWI-
independent pathway.
The ovarian carcinoma cell line A2780 showed consid-
erable activation of HERVK gag transcript levels upon a
relatively moderate reduction of TEX19. A2780 cells do
not express measurable levels of PIWIL1 and the PIWI
orthologues that are expressed are not altered upon
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TEX19 depletion. This indicates that in A2780 cells
TEX19 appears to operate in a PIWI-independent mech-
anism for TE suppression, similar to that proposed for
murine placental TE regulation [35]. These findings also
demonstrated that TEX19 can act in a repressive and acti-
vating fashion for some TE transcripts in a cell- and/or
dose-dependent fashion.
Given this, we explored protein coding gene changes
with an aim of identifying changes common to all cells.
This showed that no gene transcripts were consistently
altered upon TEX19 depletion. However, coding gene
transcripts were altered (up and down) indicating that
TEX19 could regulate the transcripts/transcription of a
cohort of oncogenic protein coding genes to foster a
proliferative state, possibly in a dose-dependent fashion.
SSX2, another CTA, is a chromatin regulator [61] and
it has been inferred that it may regulate cancer cell
proliferation through transcriptional regulation [13].
Also, the germline-specific chromatin regulator ATAD2
drives various cancer progression phenotypes via tran-
scriptional regulation and is linked to poor prognoses in
various cancers and offers an important potential thera-
peutic target [62–72]. These findings indicate there are
CTAs that can directly modulate transcription, and we
postulate that TEX19 could function in a similar fashion
controlling cellular transcript levels, either at the tran-
scriptional and/or post-transcriptional levels. As for
mouse Tex19.1, TEX19 in cancer cells can operate on a
small sub-set of protein coding and/or TE transcripts,
although the latter may be indirect.
TEX19 is both cytoplasmic and nuclear in cancer cells and
testis cells
Consistent with a direct role in transcriptional regulation,
we demonstrate that human TEX19 can locate to the nu-
cleus, although there is no apparent nuclear localization/
export signals on TEX19, which might suggest nuclear
localization in response to cellular status is regulated by
interacting partners. Murine Tex19.1 interacts with the E3
ubiquitin ligase Ubr2 which contains a nuclear localization
signal, so a role for a UBR2-TEX19 interaction in human
cancers would be worthy of further investigation [73].
TEX19 nuclear localisation appears to be linked to cell
density and may be related to proliferative state, with
nuclear TEX19 being associated with proliferation.
Whilst murine Tex19.1 is predominantly localized to the
cytoplasm, nuclear Tex19.1 can be observed in placental
tissues indicating commonalities between murine and hu-
man proteins [33, 34]. Additionally, we note nuclear foci
of TEX19 in testis, germ cell tumour line NTERA2 and
LMB treated nuclei; the functional relevance, if any, is un-
known although it is a noteworthy observation.
Recently, immunohistochemistry studies indicated that
human TEX19 was localized to Sertoli cells [31]. Our
immunofluorescence analysis of co-staining with the
Sertoli cell marker vimentin did not show direct co-
localisation of the high intensity TEX19 staining
regions (although there appears to be a low intensity
TEX19 staining throughout the basal region, including
Sertoli cells), rather a close association, suggesting that
TEX19 may not be exclusively Sertoli cell specific. Fur-
thermore, IHC staining of normal testis appears to show
nuclear localization/speckling in some of the large nuclei
[31], consistent with our observation. Zhong and co-
workers [31] extended their analysis to demonstrate that
TEX19 was present in bladder cancer samples. Whilst
most of the TEX19 they observed in these samples ap-
peared to be cytoplasmic, there are clearly cells within the
tumours that exhibit some nuclear staining with the anti-
TEX19 antibodies employed [31].
TEX19 expression influences clinical outcomes
That TEX19 expression helps drive proliferative poten-
tial of cancer cells suggests that it might influence
disease progression / outcome in patients. Our analysis
of overall survival indicates that for a number of cancers,
including breast cancer and renal cancers, that there is a
significant correlation between higher TEX19 expression
and poor prognosis, supporting a potential functional
association. These analyses might be an underestimation
of the influence of TEX19 expression as our analysis was
based on splitting cancer patient cohorts based on me-
dian TEX19 expression. Use of the median split means
that the two populations being compared both have high
numbers of TEX19 expressing cancers; if TEX19 expres-
sion alone (irrespective of the levels) is sufficient to drive
cancers, then in many of our analyses a split based on
the median would not detect a correlative link between
TEX19 expression and a poor prognosis. Ideally, we
would have split all cohorts into those expressing TEX19
and those not. This approach, however, was untenable
as many data sets had an imbalance of negative vs.
positive TEX19 expressing cancers, negating statistical
analysis. Moreover, this is further complicated by the
difficulties of ascribing tumour biopsies as having no
expression given the sensitivity/depth of modern deep
RNA sequencing technologies, which can identify low
abundance transcripts for almost all annotated genes
[74]. Despite these limitations, the analysis of breast
cancers and renal cancers clearly indicate a correlative
link between high TEX19 expression and poor progno-
sis, consistent with a functional role for TEX19 as an
oncogenic proliferative driver.
Surprisingly, we observed the converse relationship for
gliomas where higher TEX19 expression is linked to a
better prognosis, suggesting it has favorable activity in
neuronal cells. This inverse influence on disease out-
come has also been observed for T-box transcription
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factors, which both positively/negatively regulate gene
expression during embryonic development [75]. For ex-
ample, as for TEX19, TBX3 appears to have tumour sup-
pressing activity in glioblastomas [76] but oncogenic
activity in a number of solid tumours (for examples, see
[77–79]; for review, see [75]). This commonality between
T-box transcription factors and TEX19 could infer a
functional link in the distinct regulation of developmen-
tal/proliferative genes in distinct cancer types. The fac-
tors that set neuronal tumours apart from other tumour
types are likely to be multifold, however, it is noteworthy
that LINE-1 retrotransposition is active in somatic neur-
onal cells [80]; it is not unreasonable to postulate that
TEX19 production in neuronal malignancies could limit
LINE-1 transposition events and thus limit the evolu-
tionary capacity of the diseased genome and therefore
the aggressiveness of the tumour.
Conclusion
Here we have identified human TEX19 as a driver of
cancer cell proliferative potential. Importantly, we dem-
onstrate that depletion of TEX19 may result in S-phase
defects, however, the exact functional role of TEX19
remains unclear. Evidence is starting to emerge to indi-
cate that TEX19 is a transcriptional/transcript regulator
that has a degree of plasticity, which may be modulated
dependent upon the cell/tissue requirements. Whatever
the exact role, it is clear that TEX19 expression influ-
ences cancer prognosis and should be considered as a
highly specific target for the development of novel anti-
cancer therapeutic agents.
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